Fig. 4: Predictive performance of combination of TSR and the protein expression of PD-L1 for detecting of LNM in patients with PDAC. | British Journal of Cancer

Fig. 4: Predictive performance of combination of TSR and the protein expression of PD-L1 for detecting of LNM in patients with PDAC.

From: Tumor-stroma ratio combined with PD-L1 identifies pancreatic ductal adenocarcinoma patients at risk for lymph node metastases

Fig. 4: Predictive performance of combination of TSR and the protein expression of PD-L1 for detecting of LNM in patients with PDAC.The alternative text for this image may have been generated using AI.

a, b Representative IHC images of PD-L1-positive and -negative specimens (original magnification, Ɨ400); c, e, g, i ROC curves of the models combining TSR and PD-L1 protein expression for detecting LNM status in the training (c), validation (e), EUS-FNA (g) and pre-NAT EUS-FNA (I) cohorts. d, f, h, j Pattern-based interpretation of TSR and PD-L1 positivity in the classification of PDAC with association to lymph node Metastasis in the training (d), validation (f), EUS-FNA (h) and pre-NAT EUS-FNA (j) cohorts. EUS-FNA endoscopic ultrasound fine-needle aspiration, PD-L1 programmed cell death 1 ligand 1, TSR tumor-stroma ratio, PDAC pancreatic ductal adenocarcinoma.

Back to article page